Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
21
07
2020
accepted:
13
10
2020
pubmed:
17
12
2020
medline:
15
12
2021
entrez:
16
12
2020
Statut:
ppublish
Résumé
Volunteer infection studies using the induced blood stage malaria (IBSM) model have been shown to facilitate antimalarial drug development. Such studies have traditionally been undertaken in single-dose cohorts, as many as necessary to obtain the dose-response relationship. To enhance ethical and logistic aspects of such studies, and to reduce the number of cohorts needed to establish the dose-response relationship, we undertook a retrospective in silico analysis of previously accrued data to improve study design. A pharmacokinetic (PK)/pharmacodynamic (PD) model was developed from initial fictive-cohort data for OZ439 (mixing the data of the three single-dose cohorts as: n = 2 on 100 mg, 2 on 200 mg, and 4 on 500 mg). A three-compartment model described OZ439 PKs. Net growth of parasites was modeled using a Gompertz function and drug-induced parasite death using a Hill function. Parameter estimates for the PK and PD models were comparable for the multidose single-cohort vs. the pooled analysis of all cohorts. Simulations based on the multidose single-cohort design described the complete data from the original IBSM study. The novel design allows for the ascertainment of the PK/PD relationship early in the study, providing a basis for rational dose selection for subsequent cohorts and studies.
Identifiants
pubmed: 33326705
doi: 10.1111/cts.12934
pmc: PMC7993277
doi:
Substances chimiques
Antimalarials
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
712-719Informations de copyright
© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Références
Br J Clin Pharmacol. 2016 Aug;82(2):412-21
pubmed: 27062080
Malar J. 2017 Aug 25;16(1):352
pubmed: 28841864
Lancet Infect Dis. 2017 Jun;17(6):626-635
pubmed: 28363636
Antimicrob Agents Chemother. 2016 May 23;60(6):3669-75
pubmed: 27044554
Br J Clin Pharmacol. 2013 Feb;75(2):524-37
pubmed: 22759078
Clin Trials. 2016 Jun;13(3):358-66
pubmed: 26908536
Malar J. 2016 Sep 13;15:469
pubmed: 27624471
PLoS One. 2011;6(8):e21914
pubmed: 21887214
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
N Engl J Med. 2017 Jul 6;377(1):62-70
pubmed: 28679092
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16
pubmed: 15000422
J Antimicrob Chemother. 2016 Sep;71(9):2620-7
pubmed: 27272721
J Infect Dis. 2016 Jul 1;214(1):105-13
pubmed: 27056954